1780-42-3

Basic information

• Product Name: 2,4,6-trichloro-5-isopropylpyriMidine
• Synonyms: 2,4,6-trichloro-5-isopropylpyriMidine;PyriMidine, 2,4,6-trichloro-5-(1-Methylethyl)-
• CAS NO: 1780-42-3
• Molecular Formula: C₇H₇Cl₃N₂
• Molecular Weight: 225.50288
• Mol File: 1780-42-3.mol

Chemical Properties

• Boiling Point: 243.8ºC at 760 mmHg
• Flash Point: 124.8ºC
• Appearance: /
• Density: 1.393g/cm3
• Vapor Pressure: 0.0492mmHg at 25°C
• Refractive Index: 1.546
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2,4,6-trichloro-5-isopropylpyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4,6-trichloro-5-isopropylpyriMidine(1780-42-3)
• EPA Substance Registry System: 2,4,6-trichloro-5-isopropylpyriMidine(1780-42-3)

Safety Data

• Hazardous Substances Data: 1780-42-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,4,6-trichloro-5-isopropylpyriMidine is used as a building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
2,4,6-trichloro-5-isopropylpyriMidine is used as a fungicide and acaricide for controlling fungal and pest infestations in crops, ensuring the protection and yield of agricultural products.
Used in Pesticide Formulation:
2,4,6-trichloro-5-isopropylpyriMidine is used as a component in the formulation of pesticides and herbicides, leveraging its effectiveness against fungal and pest infestations in crops.
Used in Organic Chemistry Research:
2,4,6-trichloro-5-isopropylpyriMidine is used as an intermediate in the synthesis of various organic compounds, playing a crucial role in advancing the field of organic chemistry.

InChI:InChI=1/C7H7Cl3N2/c1-3(2)4-5(8)11-7(10)12-6(4)9/h3H,1-2H3

Upstream product

• 7391-69-7 5-isopropylbarbituric acid 
• 108-20-3 di-isopropyl ether 
• 759-36-4 diethyl isopropylmalonate 
• 7391-69-7 5-isopropylbarbaric acid 

Downstream Products

• 1006302-65-3 (3-cyano-5-methyl-phenyl)-(2,6-dichloro-5-isopropyl-pyrimidin-4-yl)-carbamic acid tert-butyl ester 
• 1006302-74-4 2,4-bis(benzyloxy)-6-chloro-5-isopropylpyrimidine 
• 291275-22-4 2,4-dichloro-5-isopropyl-6-[N-(3',5'-dimethylphenyl)formylamido]pyrimidine 
• 1310053-32-7 6-[4-(2-methoxyphenyl)-1-piperazinyl]-5-isopropyluracil 
• 1310053-31-6 6-(4-phenyl-1-piperazinyl)-5-isopropyluracil 
• 1006300-37-3 3-(2,6-Dichloro-5-isopropyl-pyrimidin-4-yloxy)-5-methyl-benzonitrile 
• 225232-14-4 6-benzyl-2,4-dichloro-5-isopropylpyrimidine 
• 171048-69-4 6-(3,5-dimethylbenzyl)-5-isopropyl-2,4-pyrimidinedione 
• 225232-60-0 2,4-dimethoxy-6-(3,5-dimethylbenzyl)-5-isopropylpyrimidine 
• 225232-58-6 6-benzyl-2,4-dimethoxy-5-isopropylpyrimidine 
• 176519-55-4 6-benzyl-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 149950-60-7 Emivirine 
• 149950-61-8 I-EBU-dm 
• 1006302-21-1 2,4-dichloro-5-isopropyl-6-(2,3,5-trimethyl-phenoxy)-pyrimidine 

Relevant articles and documents

1,1,1-TRICHLORO-3--3,4-EPOXYBUTANE

The synthesis of 1,1,1-trichloro-3--3,4-epoxybutane has been accomplished in nine steps from diethyl malonate and urea.The epoxide was prepared from the olefinic precursor via oxidation with anhydrous trifluoroperacetic acid in a non-buffered system.Product isolation from trifluoroacetic acid solution demonstrates an unexpected stability of this class of epoxides toward protonic media.

Molecular conformational analysis, reactivity, vibrational spectral analysis and molecular dynamics and docking studies of 6-chloro-5-isopropylpyrimidine-2,4(1H,3H)-dione, a potential precursor to bioactive agent

FT-IR and FT-Raman spectra of 6-chloro-5-isopropylpyrimidine-2,4(1H,3H)-dione were recorded and analyzed. The vibrational wavenumbers were computed using DFT quantum chemical calculations and the data obtained from wavenumber calculations are used to assign the experimentally obtained bands. Potential energy distribution was done using GAR2PED software. The geometrical parameters of the title compound are in agreement with the XRD results. NBO analysis, frontier molecular orbital and first and second hyperpolarizability and molecular electrostatic potential results are also reported. The possible electrophile attacking sites of the title compound is identified using MEP surface plot study. Molecule sites prone to electrophilic attacks were identified using average local ionization energy surfaces, while further insight into the local reactivity properties of the title molecule has been gained by calculation of Fukui functions. Intra-molecular non-covalent interactions have been detected and visualized. Degradation properties based on autoxidation and hydrolysis have been investigated by calculation of bond dissociation energies and radial distribution functions, respectively. From the molecular docking study, the ligand binds at the active site of the substrate by weak non-covalent interactions and amino acids Leu89 forms alkyl interaction with the CH3 groups and Glu90 amino acid forms π-anion interaction with the pyrimidine ring and Thr369 and Ser366 amino acids form H-bond interaction with the [Formula presented] and NH group, respectively. From the conformational analysis, the calculated structures show that the C6C9C10 angle in the most stable form is about 8° smaller compared to the C8C9C10 angle, indicating a higher repulsive force between the (CH3)2HC– moiety and the chlorine atom due to the size of chlorine compared to oxygen atoms.

HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods useful as inhibitors of KDM5 for the treatment or prevention of cancer.

Synthesis and antimicrobial activity of some novel 5-alkyl-6-substituted uracils and related derivatives

6-Chloro-5-ethyl-, n-propyl- and isopropyluracils 5a-c were efficiently prepared from the corresponding 5-alkybarbituric acids 3a-c via treatment with phosphorus oxychloride and N,N-dimethylaniline to yield the corresponding 5-alkyl-2,4,6-trichloropyrimidines 4a-c, which were selectively hydrolyzed by heating in 10% aqueous sodium hydroxide for 30 minutes. The reaction of compounds 5a-c with 1-substituted piperazines yielded the corresponding 5-alkyl-6-(4-substituted-1-piperazinyl)uracils 6a-j. The target 8-alkyltetrazolo[1,5-f]pyrimidine-5,7(3H,6H)-diones 7a-c were prepared via the reaction of 5a-c with sodium azide. Compounds 6a-j and 7a-c were tested for in vitro activities against a panel of Gram-positive and Gram-negative bacteria and the yeast-like pathogenic fungus Candida albicans. Compound 6h displayed potent broad-spectrum antibacterial activity, while compound 6b showed moderate activity against the Gram-positive bacteria. All the tested compounds were practically inactive against Candida albicans.

N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase

A series of N1-alkyl pyrimidinediones were designed, synthesized and evaluated as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Our efforts identified compound 10b, which represents the lead compound in this series with pharmacokinetics

PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS

Compounds of Formula (I): can be prepared by a multi-step process from compounds of Formula (II): wherein G is Cl, Br or I.

NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS

The invention is related to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, ester, and/ or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Novel HIV reverse transcriptase inhibitors

The invention is related to compounds of Formula (I), (II), or (III): or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Non-nucleoside HIV-1 reverse transcriptase inhibitors, part 7. Synthesis, antiviral activity, and 3D-QSAR investigations of novel 6-(1-naphthoyl) HEPT analogues

A series of novel 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) analogues bearing a 6-(1-naphthoyl) group of non-nucleoside human immunodeficiency virus (HIV) reverse transcriptase inhibitors were synthesized and evaluated for their activity against HIV-1 and HIV-2. It was found that most of these compounds showed good activity against HIV-1. Among them, compound 5-isopropyl-6-(1-naphthoyl)-1-[(2E)-3-phenylallyl]-2,4-pyrimidinedione (23) displayed the greatest inhibitory potency (IC50=0.14 μM), which is about 35-fold more active than HEPT and DDI. To rationalize the relationships between structure and activity of these novel compounds, a three-dimensional quantitative structure-activity relationship (3D-QSAR) model was also generated. The results provided a tool for guiding the further design of more potent antiviral agents and for predicting the affinity of related compounds.

Method for preparing 5-(1-methylethyl)-6-(phenylmethyl)pyrimidine-2,4(1h,3h)-dione

The invention relates to a process for the preparation of 5-(1-methylethyl)-6 -(phenylmethyl)pyrimidine-2,4(1H,3H)-dione.